Unknown statusInterventionalPhase 3Updated Nov 4, 2014
Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis | NCT01578811 | Trialant
CompletedInterventionalPhase 2Updated Mar 18, 2013
Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis
ClinicalTrials.gov ID
NCT01578811
Lead Sponsor
SK Chemicals Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
102Actual
Last Update Posted
Mar 18, 2013Estimated
Start Date
Aug 2011
Primary Completion Date
Jun 2012Actual
Completion Date
Dec 2012Actual
Brief Summary
The purpose of this study is to Assess the Efficacy and Safety of SK-MS10 in subjects With acute and chronic gastritis.
Erosive Gastritis
Placebo
SK-MS10
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have been diagnosed as erosive gastritis by endoscopy within 1 weeks before enrollment.
Patients who voluntarily signed written informed consent may participate in the study.
Exclusion Criteria:
Pregnant or lactating female.
Patients have gastric ulcer, duodenal ulcer and GERD.
Use of any proton pump inhibitor, H2-receptor antagonist, muscarine receptor antagonist and gastrin receptor antagonist within 2 weeks before initiating study drug therapy
Patients requiring corticosteroid therapy
Severe neurological or psychological disease
History of allergic reaction to the medications used in this study
Use of other investigational drugs within 30 days prior to the study.
Patients that investigators consider ineligible for this study